Is Niraparib an imported drug?

Niraparib (Niraparib) is an imported drug. In December 2019, the State Food and Drug Administration approved Zai Lab's Class 1 innovative drug niraparib tosylate capsules (trade name: Zele) through relevant regulations. Niraparib was approved as a maintenance treatment for platinum-sensitive recurrent ovarian cancer and was approved as a first-line maintenance treatment in China in October 2020. Niraparib is the potentially best PARP inhibitor for patients with ovarian cancer due to its once-daily dosing and pharmacokinetic properties, including its ability to cross the blood-brain barrier. As maintenance therapy for recurrent ovarian cancer (NOVA study), treatment with niraparib reduced the risk of disease progression or death by 73% in patients with germline BRCA mutations and by 55% in patients without germline BRCA mutations.